Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Series A funding round led by Angelini Ventures’, the investment arm of Italian industrial group Angelini Industries. The ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine levied ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

As principal and co-founder of Sierra Pacific Constructors and a second-generation builder, Cary Gerhardt remains active in ...

Kash is known to Israelis mainly for his books "Success Tactics You Won't Learn in Business School" "Freedom from Disease" ...

Sierra Pacific Constructors principal and cofounder Ken La Spada is responsible for a wide diversity of activities for SPC, ...

Detailed price information for Senti Biosciences Inc (SNTI-Q) from The Globe and Mail including charting and trades.